Pneumatic displacement of submacular hemorrhage: safety, efficacy, and patient selection.
OBJECTIVE
To investigate the safety and efficacy of pneumatic displacement of submacular hemorrhage without the use of intravitreal tissue plasminogen activator (tPA).


METHODS
In a prospective, consecutive, single-center, noncomparative, interventional case series, 20 consecutive patients with submacular hemorrhage due to various etiologies (duration, 1-30 days; visual acuity, hand movements to 20/125) were treated with intravitreal perfluoropropane gas injection followed by prone positioning for 5 days to 7 days. Patients were observed 1 day, 7 days, 30 days, 3 months, 6 months, and 1 year after the procedure.


RESULTS
Submacular blood was completely or partially displaced from the fovea in 16 of 20 eyes within 7 days after the injection. Mean best-corrected visual acuity improved from 1.6 to 0.72 logarithm of minimum angle of resolution, which was statistically significant (Wilcoxon signed rank test, P = 0.001). Final visual acuity was 20/63 or better in 10 eyes (50%). The change in proportion of eyes with best-corrected visual acuity of 20/63 or better after treatment was statistically significant (McNemar test, P = 0.002). Four patients developed nonresolving vitreous hemorrhage, which necessitated vitrectomy.


CONCLUSIONS
The results of pneumatic displacement of submacular hemorrhage using perfluoropropane gas are encouraging, thus questioning the role of tPA in the management of such cases.
Gopalakrishan
Mahesh
M
Giridhar Eye Institute, Kadavanthra, Cochin, Kerala, India. gririeye@vsnl.com
Giridhar
Anantharaman
A
Bhat
Savita
S
Saikumar
Seshadri Jenardhanan
SJ
Elias
Anna
A
N
Sandhya
S
D000328:Adult; D000368:Aged; D005260:Female; D005466:Fluorocarbons / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007267:Injections; D008297:Male; D008875:Middle Aged; D018579:Patient Selection; D011312:Pressure; D016684:Prone Position; D011446:Prospective Studies; D012166:Retinal Hemorrhage / Q000628:therapy*; D016896:Treatment Outcome; D014792:Visual Acuity; D014822:Vitreous Body
D005466:Fluorocarbons; C042852:perflutren